CSCI — COSCIENS Biopharma Share News
0.000.00%
Last trade - 00:00- CA$9.55m
- CA$4.91m
- $7.50m
Refile: Canada's COSCIENS Biopharma Q2 net loss narrows on higher sales
Canada's COSCIENS Biopharma Q1 net income turns positive on discontinued German operations
Brief: Cosciens Biopharma Inc Not Aware Of Material Undisclosed Information Amid Recent Trading Activity
Brief: Cosciens Provides Strategic Update
Brief: Cosciens Biopharma Announces Leadership Change
Brief: COSCIENS Biopharma - Enters Resolution Agreement With Goodwood, Goodwood Fund, And Puccetti Funds Management
Brief: COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results And Provides A Corporate Update
Brief: Cosciens Biopharma's early-stage study of anti-inflammatory treatment shows positive results, to start mid-stage study to test efficacy
Brief: Cosciens Biopharma Announces Change To Board Of Directors
Brief: Cosciens Biopharma Inc. Provides Updates On Merger Integration, Management Succession Plans And Ongoing Development Programs
Brief: Goodwood Inc Reports 7.2% Stake In Cosciens Biopharma As Of Aug 29 - SEC Filing
Cosciens slides on trial failure of growth hormone deficiency diagnostic drug
Brief: Aeterna Zentaris Inc. Announces Name Change To Cosciens Biopharma Inc.
Brief: Aeterna Zentaris Announces Last Patient Last Visit In Pivotal Detect-Trial For The Diagnosis Of Childhood-Onset Growth Hormone Deficiency
Brief: Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
Brief: Aeterna Zentaris Shares Expected To Commence Trading On TSX & Nasdaq On Post-Consolidation Basis
Brief: Ceapro Receives Final Court Approval For Merger With Aeterna Zentaris
Brief: Aeterna Zentaris Completes Enrollment In Ongoing Detect-Trial For Diagnosis Of Childhood-Onset Growth Hormone Deficiency
Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris And Ceapro Securityholders Vote For Arrangement To Approve Merger